.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,915,275

« Back to Dashboard

Claims for Patent: 7,915,275

Title:Use of polymorphic forms of rifaximin for medical preparations
Abstract: The present invention relates to Rifaximin polymorphic forms .alpha., .beta. and .gamma., to their use in medicinal preparations for the oral or topical route and to therapeutic methods using them.
Inventor(s): Viscomi; Giuseppe C. (Bologna, IT), Campana; Manuela (Bologna, IT), Confortini; Donatella (Bologna, IT), Barbanti; Miriam (Bologna, IT), Calanni; Fiorella (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:11/873,841
Patent Claims: 1. A method of treating bacterial infection in a patient suffering from a bowel related disorder comprising administering to a patient in need thereof a solid pharmaceutical composition comprising a therapeutically effective amount of one or more of Form .alpha., Form .beta., or Form .gamma. polymorph of rifaximin and a pharmaceutically acceptable excipient or carrier, wherein the amount of each of Form .alpha., Form .beta., or Form .gamma. polymorph of rifaximin present in said pharmaceutical composition is an amount to control the amount of systemic absorption of said rifaximin, wherein the rifaximin Form .alpha. has x-ray powder diffraction pattern peaks at about 7.4.degree.; 19.7.degree.; 21.0.degree. and 22.1.degree. 2-.theta., wherein the rifaximin Form .beta. has x-ray powder diffraction pattern peaks at about 5.4.degree.; 9.0.degree.; and 20.9.degree. 2-.theta., and wherein the rifaximin Form .gamma. has x-ray powder diffraction pattern peaks at about 5.0.degree., 7.1.degree., and 8.4.degree. 2-.theta..

2. The method of claim 1, wherein bowel related disorder is selected from the group consisting of irritable bowel syndrome, traveler's diarrhea, small intestinal bacterial overgrowth, Crohn's disease, chronic pancreatitis, pancreatic insufficiency, and colitis.

3. The method of claim 1, wherein the pharmaceutical composition is administered orally.

4. The method of claim 1, wherein the pharmaceutical composition is administered topically.

5. The method of claim 1, wherein the rifaximin Form .alpha. has a water content of less than 4.5%; the rifaximin Form .beta. has a water content of greater than or equal to 4.5%; and the rifaximin Form .gamma. has a water content from about 0% to about 2%.

6. The method of claim 5, wherein the rifaximin Form .beta. has a water content of greater than or equal to 4.5%.

7. The method of claim 5, wherein the rifaximin Form .gamma. has a water content from about 0% to about 2%.

8. The method of claim 1, wherein after administering the polymorph Form .alpha. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5.5 ng/ml.

9. The method of claim 8, wherein the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h.

10. The method of claim 8, wherein the bioavailable plasma AUC.sub.0-24h is between about 0.0 and about 100 ngh/ml, and the bioavailable plasma AUC.sub.0-inf is between about 0.0 and 110 ngh/ml.

11. The method of claim 1, wherein after administering the polymorph Form .beta. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 3.7 ng/ml.

12. The method of claim 11, wherein the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h.

13. The method of claim 11, wherein the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 40 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 50 ngh/ml.

14. The method of claim 1, wherein the rifaximin Form .beta. has a dissolution rate of from about 0.001 to about 0.016 mg/min/cm.sup.2.

15. The method of claim 1, wherein after administering the polymorph Form .gamma. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5000 ng/ml.

16. The method of claim 15, wherein the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h.

17. The method of claim 15, wherein the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 22000 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 22000 ngh/ml.

18. The method of claim 1, wherein the rifaximin Form .gamma. has a dissolution rate of from about 0.1 to about 0.16 mg/min/cm.sup.2.

19. The method of claim 5, wherein the rifaximin Form .alpha. has a water content of less than 4.5%.

20. The method of claim 5, wherein after administering the polymorph Form .alpha. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5.5 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h is between about 0.0 and about 100 ngh/ml, and the bioavailable plasma AUC.sub.0-inf is between about 0.0 and 110 ngh/ml.

21. The method of claim 5, wherein after administering the polymorph Form .beta. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 3.7 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 40 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 50 ngh/ml.

22. The method of claim 5, wherein the rifaximin Form .beta. has a dissolution rate of from about 0.001 to about 0.016 mg/min/cm.sup.2.

23. The method of claim 5, wherein after administering the polymorph Form .gamma. to a patient, the bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5000 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 22000 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 22000 ngh/ml.

24. The method of claim 5, wherein the rifaximin Form .gamma. has a dissolution rate of from about 0.1 to about 0.16 mg/min/cm.sup.2.

25. The method of claim 1, wherein after administering the polymorph Form .alpha. to a patient, bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5.5 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h is between about 0.0 and about 100 ngh/ml, and the bioavailable plasma AUC.sub.0-inf is between about 0.0 and 110 ngh/ml; wherein after administering the polymorph Form .beta. to a patient, bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 3.7 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 40 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 50 ngh/ml; and wherein after administering the polymorph Form .gamma. to a patient, bioavailable plasma concentration of the rifaximin reaches a maximum value (C.sub.max) from about 0.0 ng/ml to about 5000 ng/ml; the C.sub.max is reached within a time (t.sub.max) from about 1.0 h to about 6.0 h; and the bioavailable plasma AUC.sub.0-24h comprises between about 0.0 and about 22000 ngh/ml and the bioavailable plasma AUC.sub.0-inf comprises from about 0.0 to about 22000 ngh/ml.

26. The method of claim 25, wherein the rifaximin Form .alpha. has a water content of less than 4.5%.

27. The method of claim 25, wherein the rifaximin Form .beta. has a water content of greater than or equal to 4.5%.

28. The method of claim 25, wherein the rifaximin Form .gamma. has a water content from about 0% to about 2%.

29. The method of claim 25, wherein the rifaximin Form .beta. has a dissolution rate of from about 0.001 to about 0.016 mg/min/cm.sup.2.

30. The method of claim 25, wherein the rifaximin Form .gamma. has a dissolution rate of from about 0.1 to about 0.16 mg/min/cm.sup.2.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc